RNA vaccines in infectious diseases: A systematic review

Infectious diseases are a major health concern worldwide, especially as they are one of the main causes of mortality in underdeveloped and developing countries. Those that are considered emerging and re-emerging are characterized by unpredictability, high morbidity and mortality, exponential spread,...

Full description

Saved in:
Bibliographic Details
Published in:Microbial pathogenesis 2023-11, Vol.184, p.106372-106372, Article 106372
Main Authors: Beirigo, Emília de Freitas, Franco, Pablo Igor Ribeiro, do Carmo Neto, José Rodrigues, Guerra, Rhanoica Oliveira, de Assunção, Thaís Farnesi Soares, de Sousa, Isabella de Oliveira Ferrato, Obata, Malu Mateus Santos, Rodrigues, Wellington Francisco, Machado, Juliana Reis, da Silva, Marcos Vinicius
Format: Article
Language:English
Subjects:
Animals
Communicable Diseases
COVID-19
Humans
Infectious disease
Mice
mRNA Vaccines
Nucleic Acid-Based Vaccines
RNA
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Infectious diseases are a major health concern worldwide, especially as they are one of the main causes of mortality in underdeveloped and developing countries. Those that are considered emerging and re-emerging are characterized by unpredictability, high morbidity and mortality, exponential spread, and substantial social impact. These characteristics highlight the need to create an “on demand” control method, with rapid development, large-scale production, and wide distribution. In view of this, RNA vaccines have been investigated as an effective alternative for the treatment and prevention of infectious diseases since they can meet those needs and are considered safe, affordable, and totally synthetic. Therefore, this systematic review aimed to evaluate the use of RNA vaccines for infectious diseases from experimental, in vivo, and in vitro studies. PubMed, Web of Science, and Embase were searched for suitable studies. Additionally, further investigations, such as grey literature checks, were performed. A total of 723 articles were found, of which only 41 met the inclusion criteria. These studies demonstrated the potential of using RNA vaccines to control 19 different infectious diseases, of which COVID-19 was the most studied. Similarly, viruses comprised the largest number of reported vaccine targets, followed by protozoa and bacteria. The mRNA vaccines were the most widely used, and the intramuscular route of administration was the most reported. Regarding preclinical experimental models, mice were the most used to evaluate the impact and safety of the RNA vaccines developed. Thus, although further studies and evaluation of the subject are necessary, it is evident that RNA vaccines can be considered a promising alternative in the treatment and prophylaxis of infectious diseases. [Display omitted] •Most studies reviewed investigated the potential of RNA vaccines against viruses, followed by protozoa and, lastly, bacteria.•mRNA model was the most used among the included studies.•Most of the studies that developed RNA vaccines for infectious diseases used the murine model Mus musculus.•mRNA vaccines has potential for the control and prophylaxis of infectious diseases in preclinical studies.
ISSN:0882-4010
1096-1208
DOI:10.1016/j.micpath.2023.106372